Annual report [Section 13 and 15(d), not S-K Item 405]

Income Taxes - Additional Information (Details)

v3.26.1
Income Taxes - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Tax Disclosure [Line Items]    
Increase in valuation allowance $ 47,127  
Deferred Tax Assets, Operating Loss Carryforwards, Local 257,607  
Deferred Tax Assets, Operating Loss Carryforwards, Federal 319,886  
Federal, state and local net operating loss carryforwards 83,014 $ 44,369
Deferred tax assets, operating loss carryforwards, not subject to expiration 319,636  
Deferred tax assets, operating loss carryforwards, subject to expiration $ 250  
Operating loss carryforwards state commencement of expiration date 2037  
Federal and state research and development tax credit carryforwards expiration date 2038 years  
Research and development tax credits $ 25,050 $ 16,296
Research and development credits $ 13,821  
Percentage of eligible tax positions for recognition 50.00%  
Unrecognized income tax benefits that would affect effective tax rate $ 0  
Federal [Member]    
Income Tax Disclosure [Line Items]    
Research and development tax credits $ 25,044  
Deferred tax assets tax credit carryforwards commencement of expiration date 2037  
State [Member]    
Income Tax Disclosure [Line Items]    
Federal, state and local net operating loss carryforwards $ 255,101  
Research and development tax credits $ 6  
Deferred tax assets tax credit carryforwards commencement of expiration date 2042  
Orphan Drug Credits [Member]    
Income Tax Disclosure [Line Items]    
Research and development credits $ 11,223